We are developing immuno-oncology solutions that harness the body’s immune system to recognize and fight cancer more effectively, alongside precision therapies that act on specific molecular pathways.
We at Lupin continue to strengthen our oncology presence by expanding capabilities across research, manufacturing, and patient engagement. Our approach spans the full spectrum of cancer care, from conventional treatment methodologies to targeted therapies and our ongoing foray into immunotherapy.
We partner with and educate healthcare professionals, offer affordable cancer care to patients, and encourage tertiary care with patient support programs. We continue to advance innovation through our Research and Development wing, with a strategic focus on immunotherapy and next-generation targeted therapies.
We are developing immuno-oncology solutions that harness the body’s immune system to recognize and fight cancer more effectively, alongside precision therapies that act on specific molecular pathways.
Our research pipeline includes novel candidates across these areas, with several programs progressing through early clinical development.
We have established a dedicated oncology manufacturing block at our Vizag facility in India. This unit significantly enhances our capacity for High-potency Active Pharmaceutical Ingredients (HPAPIs).
Beyond medication, we are committed to improving cancer awareness and early diagnosis.
Through community engagement programs such as Prothsahan, we promote early detection and education by sharing survivor stories and expert insights. Through Niramai™, we also showcase strong partnerships that help offer technology-enabled screening initiatives, supporting early detection and improved outcomes.
Our oncology portfolio addresses multiple cancer types and targets each organ through various therapeutic approaches.
As per clinical evidence, breast cancer affects approximately 1 in 8 women across various age groups globally. At Lupin, we actively support early detection through awareness programs and screening, promoting clinical and self-breast examination practices, as well as timely diagnostic interventions, to enable earlier diagnosis and improved clinical outcomes.
Head and neck cancers comprise a heterogeneous group of malignancies arising from the oral cavity, pharynx, and larynx also from less common sites like salivary glands, and nose, sinuses, muscles, or nearby structures. These cancers are among the most prevalent malignancies in India and are a well-established association with tobacco use.
This therapeutic segment is addressed through targeted treatment approaches, including Epidermal Growth Factor Receptor (EGFR) inhibitor–based therapies, which enable more precise, biomarker-driven and effective disease management.
Ovarian cancer is characterized by the malignant transformation and uncontrolled proliferation of specific cells within the ovaries or fallopian tubes. Our portfolio encompasses targeted therapies directed at specific molecular pathways, facilitating personalized treatment approaches and improving patient access to advanced therapeutic modalities.
Lung cancer remains one of the most common cancers worldwide, often diagnosed at advanced stages due to limited early symptoms. Advancements in targeted therapies and precision medicines are improving outcomes, particularly for patients with specific genetic profiles, enabling more personalized and effective treatment strategies.
Blood cancers such as leukemia, lymphoma, and multiple myeloma require specialized therapies targeting abnormal proliferation of blood-forming cells. Treatment often involves a combination of chemotherapy, targeted therapies, and monoclonal antibodies.
We offer affordable, high-quality therapies in this segment. For example, our Rituximab range of medication offers cost-effective treatment to patients without compromising on efficacy and safety.
Palliative care is a critical component of comprehensive oncology management, focused on managing the disease and treatment-related symptoms such as pain, fatigue, infections, anemia, and chemotherapy-induced neutropenia. Our supportive care portfolio includes therapies designed to mitigate treatment-related adverse effects, reduce complications, and improve overall quality of life.
Disclaimer: The content on this website/webpage relates to a specific therapy/therapeutic area and is intended solely for informational and educational purposes for healthcare professionals and patients across India and other global locations, is not intended to substitute professional medical advice, diagnosis, or treatment. Advice from a physician or other qualified healthcare professional must be sought for any queries regarding a medical condition or treatment. Information on this website/webpage should not be solely used or relied upon in the absence of or delay in receiving professional medical advice. While Lupin makes reasonable efforts to ensure that the information is accurate and up to date, it makes no representations or warranties regarding its completeness or accuracy and accepts no liability for reliance on such information. The information on this website/webpage is not a substitute for prescribing information or patient information leaflets accompanying any medicinal product. The information on this website/webpage is subject to change without notice and may not reflect the most current medical, scientific, or regulatory developments. All content on this website/webpage is the intellectual property of Lupin and shall not be reproduced, modified, distributed, or used for any commercial purpose without the prior written consent of Lupin.
Our oncology portfolio includes targeted therapies and supportive treatments used in cancer management across global markets.
Pertuzumab Injection
In treatment of metastatic breast cancer.
Rituximab Injection
Targeted therapy used for non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and selected autoimmune conditions.
Olaparib Tablet
In treatment of ovarian cancer, breast cancer, and pancreatic cancer.
Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Injection
Febrile Neutropenia.
Trastuzumab Injection
In treatment of patients with HER2-positive breast cancer.
Bevacizumab Injection
In treatment of colorectal cancer and ovarian cancer.
We continue to strengthen our cancer care capabilities through research investments, global partnerships, and early detection initiatives.
Cancer care is evolving rapidly with advancements in targeted therapies, immunotherapies and supportive care. We at Lupin are at the forefront of this transformation through investments in oncology research, specialized manufacturing, and patient-focused initiatives.
By strengthening capabilities across the oncology value chain, we continue to support patients, healthcare professionals, and the global audience in battling cancer.
